Pharma Research Library | Pharma Info Index Research | Innovation | Opportunities |
Anicet Kassi Adoubi*1, Maboury Diao2, Mamadou Saïdou Sow3, Khadidiatou Dia4, Abdou Issa Ndong3, Shalini Kumar5, Rahul Kotwal5, Gunjan Surendranath5, Mahima Shankar Tiwari5, Rachita Narsaria6
1Associate Professor of Cardiovascular Diseases University of Bouaké, Ivory Coast, Africa
2Head of Cardiology Hospital Aristide le Dantec, Dakar, Senegal, Africa
3Youssou mbargane de Rufisque, Senegal
4Principle Hosp. Dakar, Senegal
5Ajanta Pharma Ltd. – Satellite Gazebo, B Wing, 301/302, 3rd, Extension, Chakala, Andheri Ghatkopar Link Road, Andheri (East), Mumbai – 400093, India
6Spellbound Inc. – 1401/B, Shikhar Kunj, Upper Govind Nagar, Malad East, Mumbai- 400 097, India
A B S T R A C T
Background: Hypertension increases the incidence of congestive heart failure, myocardial infarction, and ischemic stroke. In previous studies, metoprolol succinate extended release (XL) has been identified as a plausible antihypertensive medication compared to others. Apart from angiotensin II receptor antagonists, this β-blocker effectively reduces mortality and hospitalisation rate due to cardiovascular accidents. Aim: The aim was to identify the impact of metoprolol succinate XL 50/100mg on hypertensive patients for 3 months as part of a post-market surveillance study involving the African population. Methods: Out of 200 patients, a total of 184 patients were enrolled on the study. Results: Metoprolol succinate XL led to a significant decrease in the mean systolic blood pressure (SBP), mean diastolic blood pressure (DBP), and mean heart rate (HR) at 4th, 8th, and 12th-week from baseline (p<0.0001). 39.50%, 18%, 61.50%, and 45.50% of patients went from Grade 1 to normal, Grade 2 to Normal, High Normal to Normal and isolated systolic hypertension to Normal categories of BP, respectively. Large effect size was noticed in analyses, as estimated by Cohen’s d-value, which implied a practical significance of using the drug in the study population with respect to lowering BP and HR. Mean SBP, DBP, and HR change was higher in the baseline to 4-week, 8-week, and 12-week groups compared to inter-weekly changes. Moreover, mean baseline SBP and DBP were higher in groups administered with 50mg of the drug. Conclusion: These findings suggest that metoprolol succinate XL 50/100mg significantly lowers mean BP and HR among African hypertensive patients.
Keywords: Metoprolol succinate, extended-release, hypertension, systolic, diastolic, heart rate
